Belgian real life non-interventional study (NIS) on Xarelto in non-valvular Atrial Fibrillation (AF) patients treated for the prevention of stroke and systemic embolism (BOX-AF)
The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valvular AF treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.
- Adult patients ≥ 18 years old with a confirmed diagnosis of non-valvular atrial fibrillation - Patients must in addition present with at least one of following risk factors: -- prior stroke, TIA (transient ischemic attack) or non-CNS (central nervous system) systemic embolism -- left ventricular ejection fraction of < 40% -- symptomatic heart failure, New York Heart Association class 2 or higher -- age ≥75 years -- age ≥65 years in combination with either diabetes, coronary disease or arterial hypertension
- Patients who do not fulfil the Belgian reimbursement criteria
Many locations, Belgium
E-mail: [email protected]
Phone: Not Available
Belgian real life non-interventional study (NIS) on Xarelto® in non-valvular Atrial Fibrillation (AF) patients treated for the prevention of stroke and systemic embolism (BOX-AF)